We would love to hear your thoughts about our site and services, please take our survey here.
2nd part of article, great to see something positive
work will be carried out by a team from the University of Pennsylvania, led by Professor Nolle Frey, who has headed a number of important CAR-T clinical trials.
The entre was provided by Professor Carl June, the 'father' of CAR-T, and his colleague, Dr Saar Gill, who was involved in the preclinical research on HEMO-CAR-T.
On the university's involvement, Sandler said: 'This isn't a situation where we've paid [UPenn] to carry out the work. They don't work like that. All along it been data driven.'
While no guarantee of success, it provides validation for the science behind the efforts of Hemogenyx.
So expensive is the process of creating individual CAR-T treatments, that cash raised in February may be enough to dose three patients
Hemogenyx will look to further non-dilutive funding to assess a cohort of around 18 AML sufferers, which will take it to the phase II stage of the clinical evaluation.
This is key, as it is the point that big pharma has weighed into the sector with the deals mentioned above.
If all of this suggests that Hemogenyx is a one-trick pony, then that would be misleading.
Before moving into the area of CAR-T, its team together with Eli Lilly, developed a breakthrough that enhances bone marrow and stem cell transplant procedures
The approach focuses on the initial critical stages of eradicating diseased cells and replacing them with healthy ones, using a CDX bi-specific antibody that is both safer and more effective than traditional chemotherapy.
'We decided to do something that other people wouldn't touch at that time,' says Sandler. This has been a theme with all of Hemogenyx's research - attempting the difficult.
As such, the company has created and is a leader in the field of chimeric bait receptors. Put simply, CBRs are designed to attract and catch harmful cells, like cancer cells, by pretending to be something the harmful cells want to attach to.
Once the bad cells latch onto these bait receptors, the immune system can easily find and destroy them.
Its research is being deployed to combat brain cancers such as glioblastoma and neurodegenerative diseases where delivering therapeutics across the blood-brain barrier has long been problematic.
At the same time, it is working on intranasal delivery of CBRs to tackle airborne viral infections, an area of research germane to the civil defence industry and the military.
While Sandler wouldn't be drawn on exactly who he is talking to, there are discussions with parties interested in helping develop the viral infections defense deployment, the CEO confirmed.
'We are talking to institutions and agencies,' Sandler says. 'There is a lot of interest and we are moving these conversations along.
The Ice Age-like big freeze across the small-cap market in the UK means none of company's potential has been captured in the current share price, which values Hemogenyx at a bargain basement £21million
From DM,
Investors can now add Hemogenyx Pharmaceuticals to the watch list after it pulled off the near impossible by raising $4.2million at a time when investors have largely gone into hibernation. This feat of resourcefulness, which will fund the initial stages of a first-in-human study of the drug developer's lead asset, HEMO-CAR-T, only tells part of the story. The pedigree of the scientific team backing the efforts of Hemogenyx is impressive.
At the same time, the interest in the next generation of CAR-T – the type of therapy that Hemogenyx is developing – amongst big pharma has seen the likes of AstraZeneca, Johnson & Johnson, Abbvie and Novartis top the billion-dollar threshold in milestone and royalty payments? Upfront payments, usually a good litmus test of 'real' interest from these titans of the world of drugs, have been eye-watering; in some cases up to $100million.
The reason? CAR-T offers something that the healthcare industry rarely comes up with – a curative treatment, showing the world has truly moved on from the era of me-too, once-a-day pills such as statins.
Anyway, before we delve into the nuts and bolts of the Hemogenyx investment case, it is probably worth explaining just what CAR-T therapy is and how it might revolutionise the treatment of cancers such as acute myeloid leukaemia (AML), which is the particular area of interest of this UK biotech
CAR-T, or chimeric antigen receptor T-cell therapy, redefines the battle against the disease by reprogramming the body's own natural defences, called T-cells, to recognise and kill cancer cells. This advanced form of immunotherapy involves extracting T-cells from a patient, genetically engineering them to target cancer cells, and then reintroducing these enhanced cells into the patient's bloodstream.
CAR-T has demonstrated remarkable success in tackling certain blood cancers, offering new avenues for combating previously untreatable cancers. Despite its potential, much of the research is now focused on CAR-T therapy's significant side effects, while broadening its applicability to a wider array of cancers.
Hemogenyx will use the newly raised funds to take HEMO-CAR-T into the clinic to treat AML later this year
The open-label study will test for any potential side effects from treating people with blood-borne diseases and assess how the therapy interacts with the body.
A secondary goal or 'endpoint' will be whether any of the critically ill AML patients chosen for the trial respond to the CAR-T infusion.
Under the strict guidelines laid down by the US Food & Drug Administration, patients will be dosed individually one month apart, recognising people are being administered with a potentially toxic cells.
Hemogenyx hopes to have the results from 'two, or even three patients' in time for the American Society of Hematology conference in early December.
Success at this stage would be a 30% response rate, says Dr Vladislav Sandler, chief executive and co-founder of Hemo
Rolls-Royce (LSE: RR., ADR: RYCEY) announces it has successfully kicked off the flight test campaign for its latest aero engine for the business aviation market, the Pearl 10X, on the company’s dedicated Boeing 747 flying testbed. The engine has been selected by French aircraft manufacturer Dassault to exclusively power its brand-new flagship aircraft, the Falcon 10X
https://www.rolls-royce.com/media/press-releases/2024/03-04-2024-business-aviation-pearl-10x-engine-takes-to-the-skies-for-the-first-time.aspx
Agree, moving in the right direction, was hoping for some small movement today.
This is under the radar at the moment, I do think it will suddenly have a large jump once we get more updates on the treatment trials. Could then be bought out by a large company for millions
Before the share split, the increase in the amount of shares since the split won’t prevent this from heading towards £8.40. Better company with better technology such as Ultra Fan, mix in SMR and Tufan as CEO this will keep on moving upwards
Korean Air, South Korea’s flag carrier, is in the works to order 20 Airbus A350 jets from Airbus. An official announcement might come as early as this week, according to Bloomberg.
https://airlinegeeks.com/2024/03/18/korean-air-eyeing-airbus-widebody-order/#:~:text=The%20Order,and%20restructure%20its%20growing%20fleet.
This will soon lift off very soon and catch people out, under the radar currently.
There are plenty of large buys
I do, I completed my Bed & ISA twice last year (1week period in tax year for 2022/2023) the shares were at £1.45, did the max amount allowed in both mine and the wife’s account. Profit is tax free inside my tax wrapper
No Tax to pay
Bed and ISA transactions let you take advantage of your tax-free ISA allowance even if you don't have any new money to invest. In an ISA any interest from cash savings and income from dividends are free from income tax, and your investment gains are safeguarded from capital gains tax
It would make a nice change for the company to provide more detail on Grass MATA MPL . In the Half year trading update is states that
The first scientific advisory meeting with regulators is anticipated to occur in late Q1 2024, where discussions will confirm the pathway forward for potential progression to the marketing authorisation application process.
Remember 26 January 2023, Placing to Raise £4,056,250
Has Vlad not learned anything, this was offered at 2.5p prior to any good news about FDA approval or CBR,CDX. Why sell them for less
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has successfully raised £4,056,250 (before expenses) through the allotment and issue of 162,250,000 new ordinary shares at 2.5 pence per share (the "Placing", "Placing Shares"). The Placing was conducted by Peterhouse Capital Limited and SP Angel Corporate Finance LLP as joint placing agents for the Company.
I also blame the non-executive director Peter Redmond who stated on Proactive Investors web view that he is responsible for uk matters and corporate matters and liaising with brokers for investment into HEMO, he brought them onto the stock market. What a muppet
It will now mean we probably have to wait another 6 months for any decent share price improvement. It is what it is!
Vlad’s words in the RNS are positive even if the placing price wasn't
"We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T. I would like to thank new and existing shareholders for their support and for contributing to this sizeable fundraise in difficult market conditions. The recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I am very grateful."
Happy with the facts Haywain, enjoy reading your posts which cover in great detail everything, most of us know nothing about the subject or the cutting edge treatments that are now on the table. It is refreshing to have an investor on board who also has the medical understanding to explain it to us, this only adds to the support we have for Hemo.
Just watched the results presentation in full, great speech from Turfan and his CFO, handled the Q&A session with analyst Dave Perry from JP Morgan and others really well , he mentioned he had dinner with Emirates president Sir Tim Clark and get the feeling some announcement soon
What’s not to like, it will not just produce something magical over 12 months, it is work in progress
Tufan Erginbilgic, CEO said: “Our transformation has delivered a record performance in 2023 driven by commercial optimisation, cost efficiencies and progress on our strategic initiatives. This step-change has been achieved across all our divisions, despite a volatile environment with geopolitical uncertainty, supply chain challenges and inflationary pressures.
We are managing the business differently and our significant performance improvement in the year reflects the hard work and focused actions of all our teams. We are also continuing to invest to drive future sustainable growth. Our strong delivery in 2023 gives us confidence in our 2024 guidance and is a significant step towards our mid-term targets. We are unlocking our full potential as a high-performing, competitive, resilient, and growing Rolls-Royce.”